Liquidia Technologies (LQDA) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Liquidia Technologies (NASDAQ:LQDA) from a hold rating to a sell rating in a research report report published on Wednesday.

According to Zacks, “Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company’s product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. “

Several other research analysts have also issued reports on LQDA. Needham & Company LLC initiated coverage on shares of Liquidia Technologies in a research note on Monday, August 20th. They set a buy rating and a $30.00 target price on the stock. Jefferies Financial Group began coverage on shares of Liquidia Technologies in a research note on Monday, August 20th. They set a buy rating and a $22.00 target price on the stock. Cowen began coverage on shares of Liquidia Technologies in a report on Monday, August 20th. They set an outperform rating and a $40.00 price objective on the stock. Finally, Wedbush began coverage on shares of Liquidia Technologies in a report on Tuesday, September 4th. They set an outperform rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $31.75.

Shares of NASDAQ LQDA opened at $19.94 on Wednesday. Liquidia Technologies has a 12-month low of $10.52 and a 12-month high of $38.46. The company has a current ratio of 6.27, a quick ratio of 6.27 and a debt-to-equity ratio of 0.40.

Liquidia Technologies (NASDAQ:LQDA) last issued its earnings results on Wednesday, October 31st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.26). The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.03 million. On average, sell-side analysts forecast that Liquidia Technologies will post -5.67 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. NEA Management Company LLC acquired a new position in Liquidia Technologies during the third quarter worth $68,193,000. FMR LLC acquired a new position in Liquidia Technologies during the third quarter worth $6,729,000. BlackRock Inc. acquired a new position in Liquidia Technologies during the third quarter worth $5,924,000. Vanguard Group Inc. acquired a new position in Liquidia Technologies during the third quarter worth $4,263,000. Finally, Dean Capital Investments Management LLC acquired a new position in Liquidia Technologies during the third quarter worth $1,483,000. Hedge funds and other institutional investors own 20.29% of the company’s stock.

Liquidia Technologies Company Profile

Liquidia Technologies, Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.

Recommended Story: Market Capitalization

Get a free copy of the Zacks research report on Liquidia Technologies (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply